New Brighton, May 16, 2013 – Cellectis (NYSE PA: ALCLS), the global genome engineering specialist, announced the issuance by the USPTO on May 14th, 2013 of two new US...
- Europe and International + 33 1 81 69 16 01
- USA and Canada +1 617 682 3624
News
29 Apr 2013
Paris, April 29,2013 - Cellectis (Alternext: ALCLS), the global genome engineering specialist, presented its consolidated financial statements for the 2012 fiscal year, approved...
17 Apr 2013
Paris (France), April, 17th 2013 - Cellectis bioresearch, a subsidiary of Cellectis Group (Alternext: ALCLS), the genome engineering specialist, announces the launch of VizuCELL...
08 Apr 2013
Paris (France), April 8th, 2013 - CanCELL™ cell lines are featuring gene knock-outs of the major cancer relevant oncogenes and tumor suppressor genes. This new product line...
07 Mar 2013
Cambridge, Massachusetts (USA) March 7th, 2013 - Cellectis bioresearch, a subsidiary of Cellectis Group (Alternext: ALCLS), the genome engineering specialist, announced today a...
25 Feb 2013
Paris, February 25th, 2013 – Cellectis (Alternext: ALCLS), the global genome engineering specialist, has announced its appointment of Pierre Schwich as Group Chief Financial...